证券代码:300463 证券简称:迈克生物 公告编号:2021-064 迈克生物股份有限公司 关于参加 2022 年四川辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 为进一步加强与投资者的互动交流，迈克生物股份有限公司（以下简称"公司"）将参加 由四川证监局、四川省上市公司协会与深圳市全景网络有限公司联合举办的"2022 年四川辖 区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本次活动将通过深圳市全景网络有限公司提供的互联网平台举行，投资者可登录"全景路 演"网站（http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次 互动交流，活动时间为 2022 年 9 月 16 日（周五） 14:00-17:00。 届时公司总经理吴明建先生、财务总监尹珊女士、董事会秘书史炜女士将通过网络在线交 流的方式，与投资者就公司治理、社会责任/ESG、经营状况、发展战略、风险防控、可持续 发展等投资者所关心的问题进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 迈克生物股份有 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[20] - The company's revenue for the first half of 2022 was ¥1,781,810,340.82, a decrease of 9.11% compared to ¥1,960,373,333.89 in the same period last year[32] - Net profit attributable to shareholders was ¥405,770,027.70, down 23.68% from ¥531,681,926.41 in the previous year[32] - Basic earnings per share decreased by 29.65% to ¥0.6728 from ¥0.9563 in the same period last year[32] - The company achieved a revenue of 1.782 billion, a year-on-year decrease of 9.11%, and a net profit of 406 million, down 23.68%[55] - Sales revenue from self-developed products was 1.136 billion, a decline of 1.84%, while agency product sales revenue was 626 million, down 20.17%[55] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[20] - The company emphasizes overseas market expansion, having established partnerships with over 460 distributors across 112 countries and regions, making international markets a key area for growth[46] - The company is focused on expanding its market presence and enhancing its product offerings in the molecular diagnostics sector, particularly in digital PCR technology[153] - The company plans to enhance its competitive edge by improving product quality, variety structure, R&D capabilities, and sales services in response to increasing market competition[156] Research and Development - The company has allocated 50 million RMB for research and development in new technologies for the upcoming fiscal year[20] - The company invested 12.33 million yuan in R&D during the reporting period, marking a 10.94% increase year-on-year[78] - The company has established a research and development platform that includes two major centers for reagents and instruments, focusing on continuous technological breakthroughs and new technology reserves[48] - The company has 480 ongoing R&D projects, with 135 new projects initiated in the first half of 2022[81] - R&D investment for the period amounted to approximately 123.31 million RMB, with significant allocations across various product lines[81] Product Development and Innovation - The company plans to launch three new products in the next quarter, focusing on advanced diagnostic technologies[20] - The company has developed a digital PCR product line under the molecular diagnostics platform, leveraging droplet microfluidics technology, with a focus on creating fully automated, integrated digital PCR instruments and associated reagents[46] - The company is developing a fully automated biochemical analyzer aimed at enhancing product competitiveness and is currently in the development phase[84] - The company has completed the development of urine transferrin assay kits and improved kidney function testing menu, aiming to enhance product performance and brand influence in biochemical products[87] Financial Management - No cash dividends will be distributed to shareholders for this fiscal year, as the company focuses on reinvestment[6] - The company has received non-public offering funds, resulting in a significant increase in cash and cash equivalents by 4,137.57% to ¥649,626,367.67[115] - The total investment amount for the reporting period was ¥482,323,024.91, representing an increase of 88.74% compared to ¥255,547,835.69 in the same period last year[127] - The company has allocated ¥31,000.00 million of idle raised funds to purchase bank wealth management products[135] Environmental Responsibility - The company has established a wastewater treatment station that operates normally, with total emissions of ammonia nitrogen at 0.0889 tons/year and COD at 0.7707 tons/year[177] - The company has a new emergency response plan for environmental incidents, valid until July 3, 2025[182] - The company has implemented wastewater monitoring at treatment plant outlets, measuring parameters such as flow, pH, suspended solids, and biochemical oxygen demand, with a frequency of once per season[190] - There were no administrative penalties due to environmental issues during the reporting period, indicating compliance with regulations[192] Corporate Governance and Social Responsibility - The company has established a strong corporate culture and talent team, which are essential for its long-term development and competitive advantage[96] - The company is actively involved in community service and environmental initiatives, reflecting its commitment to social responsibility[195] - The company has engaged in multiple investor communications to discuss its business performance and future strategies[166] - The company has committed to long-term stockholding and will adhere to regulations regarding stock reduction post-lockup period, with a maximum of 25% of shares held being sold annually[199]

Financial Performance - Revenue for Q1 2022 was ¥924,725,004.03, a decrease of 13.54% compared to ¥1,069,535,881.25 in the same period last year[4] - Net profit attributable to shareholders was ¥201,843,094.15, down 35.58% from ¥313,335,250.80 year-on-year[4] - Basic earnings per share decreased by 39.77% to ¥0.3399 from ¥0.5643 in the previous year[4] - Total operating revenue for the first quarter was ¥924,725,004.03, down 13.5% from ¥1,069,535,881.25 in the previous year[32] - Net profit for the quarter was ¥212,187,393.54, a decrease of 35.5% compared to ¥329,384,972.57 in the same period last year[35] - The net profit attributable to the parent company was approximately ¥201.84 million, a decrease from ¥313.34 million in the previous period, representing a decline of about 35.5%[38] - The total comprehensive income attributable to the parent company was approximately ¥201.84 million, down from ¥313.34 million, reflecting a decrease of around 35.5%[38] Cash Flow - Net cash flow from operating activities increased by 38.57% to ¥120,108,068.54, compared to ¥86,679,373.91 in the same period last year[4] - Cash flow from operating activities generated a net amount of approximately ¥120.11 million, an increase from ¥86.68 million in the previous period, representing a growth of about 38.5%[42] - Cash flow from investing activities resulted in a net outflow of approximately ¥1.07 billion, compared to a net outflow of ¥119.35 million in the previous period[45] - Cash flow from financing activities generated a net inflow of approximately ¥1.26 billion, contrasting with a net outflow of ¥15.96 million in the previous period[45] - The ending balance of cash and cash equivalents was approximately ¥926.38 million, an increase from ¥534.76 million in the previous period, reflecting a growth of about 73%[45] - The company received cash from investment of approximately ¥940 million during the investment activities[45] - The company reported a cash inflow from operating activities totaling approximately ¥821.86 million, down from ¥1.02 billion in the previous period, indicating a decrease of about 19%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,002,274,266.41, an increase of 21.86% from ¥6,566,894,132.48 at the end of the previous year[4] - Total liabilities decreased to ¥1,690,901,202.58 from ¥2,025,164,897.83, a reduction of 16.5%[30] - The company's equity attributable to shareholders increased to ¥6,057,872,980.64, up from ¥4,298,573,450.85, marking a growth of 41.0%[30] - Short-term borrowings decreased significantly to ¥335,097,332.92 from ¥530,557,969.20, a reduction of 36.8%[30] - Deferred tax assets increased to ¥163,971,729.56 from ¥161,183,123.70, indicating stable tax planning[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,218[12] - The largest shareholder, Tang Yong, holds 11.11% of shares, totaling 68,062,301 shares, with 51,046,726 shares pledged[12] - The second-largest shareholder, Wang Dengming, holds 7.43% of shares, totaling 45,534,495 shares[12] - The total number of shares with limited sale conditions for Tang Yong is 51,046,726, which are locked due to being a senior executive[16] - The total number of shares with limited sale conditions for Guo Lei is 35,774,906, with 7,933,446 shares released during the period[16] - The total number of shares with limited sale conditions for Liu Qilin is 24,845,520, which are also locked due to being a senior executive[16] - The total number of unrestricted shares held by the top ten shareholders includes 26,046,900 shares held by Chen Mei and 22,894,262 shares held by Wang Chuanying[15] - The total number of shares with limited sale conditions increased by 64,974,790 during the period, resulting in a total of 211,253,351 shares at the end of the reporting period[19] - The company has established a consistent action relationship among major shareholders, including Tang Yong, Wang Dengming, and Liu Qilin[15] - The company has a total of 154,212,007 shares with limited sale conditions at the beginning of the period[19] Strategic Initiatives - The company is actively engaging in strategic initiatives, including stock issuance and board restructuring, to enhance its operational capabilities and market position[20] - The company completed the election of its fifth board of directors and supervisory board, consisting of 6 non-independent directors and 3 independent directors[23] - The company received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets, confirming compliance with issuance conditions[20] - The company signed a tripartite supervision agreement for the special account storage of raised funds with the sponsor and the commercial bank[20] Research and Development - Research and development expenses increased to ¥46,379,511.10, up 16.4% from ¥39,826,443.24, indicating a focus on innovation[35] Financial Management - The company experienced a 44.12% reduction in financial expenses, totaling ¥7,092,225.58, due to decreased loan repayments and interest income from raised funds[11] - The company reported a decrease in accounts payable to ¥405,127,147.04 from ¥310,332,249.19, reflecting improved cash flow management[30] Audit Information - The company did not conduct an audit for the first quarter report[46]

Financial Performance - Maccura Biotechnology reported a revenue of 1.2 billion CNY for the fiscal year 2021, representing a year-over-year increase of 15% compared to 2020[39]. - The company achieved a net profit of 300 million CNY in 2021, which is a 20% increase from the previous year[39]. - The company's operating revenue for 2021 was ¥3,980,647,183.47, representing a 7.47% increase from ¥3,703,877,006.69 in 2020[46]. - The net profit attributable to shareholders for 2021 was ¥956,604,404.94, a 20.49% increase compared to ¥793,917,986.86 in 2020[46]. - The net cash flow from operating activities reached ¥1,616,683,215.88, marking a significant increase of 47.77% from ¥1,094,048,810.10 in 2020[46]. - The basic earnings per share for 2021 was ¥1.7308, up 20.77% from ¥1.4331 in 2020[46]. - The company reported a gross margin of 60% for 2021, consistent with the previous year, indicating stable cost management[39]. - The company achieved a revenue of 3.981 billion in 2021, a year-on-year increase of 7.47%, and a net profit of 957 million, up 20.49%[84]. - Sales revenue from self-developed products reached 2.3 billion, growing by 24.08%, while agency product sales declined by 9.76% to 1.635 billion[84]. - The gross profit margin for comprehensive sales increased from 53% to 58% year-on-year[84]. Market Expansion and Strategy - Maccura plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[39]. - The company is exploring potential acquisitions to enhance its product portfolio and expand its technological capabilities[39]. - The company aims to enhance its market competitiveness by promoting laboratory automation and self-sufficiency, thereby increasing its domestic market share[78]. - The company is focusing on enhancing its market presence and distribution capabilities, particularly in overseas markets, with 143 new overseas channels added during the reporting period[86]. - The company is actively pursuing strategic partnerships to facilitate market expansion and product development in emerging markets[179]. - The company is expanding its market reach with new registrations in various international markets, including significant numbers in Turkey, Egypt, and the Philippines[157]. Research and Development - The company has increased its R&D investment to strengthen its core technologies and reduce the risk of technology leakage[11]. - The company invested 25% to 30% of its net profit annually into R&D, totaling approximately 1 billion over the past five years, which is 13.4% of self-developed product revenue[92]. - The company has established three major R&D platforms covering biological raw materials, reagents, and instruments, with 906 R&D personnel accounting for 31.23% of total employees[92]. - The company has initiated a total of 346 research and development projects, expecting to deliver over 20 technological innovations and new products annually, with 433 patents held, including 203 invention patents[95]. - The company is focusing on developing advanced testing technologies, including direct chemiluminescence methods for various assays[172]. - The company is enhancing its research and development capabilities to support the launch of new diagnostic products[163]. Product Development and Innovation - The company has developed a comprehensive product line in in vitro diagnostic solutions, covering over 1,500 diagnostic reagents and more than 30 diagnostic instruments across nine major product platforms[77]. - The company has successfully launched innovative products, including the world's first creatinine reagent resistant to hydroxyphenylsulfonic acid interference and a new COVID-19 nucleic acid test kit approved for emergency use in Sichuan Province[79]. - The company has developed rapid and precise COVID-19 nucleic acid detection products, receiving registrations in multiple countries, which will strengthen its molecular detection product brand[132]. - The company is focusing on upgrading existing products based on customer and market demands, particularly in inflammation and diabetes testing[135]. - The company is expanding its product offerings in the field of autoimmune disease testing, with several new tests in the registration phase[138]. - The company has introduced a new series of COVID-19 related testing kits, including neutralizing antibody testing kits, which are also self-declared[172]. Regulatory Compliance and Quality Control - The company is committed to maintaining compliance with regulatory standards in the EU and EEA regions for its new products[164]. - The company has established a quality management system certified by TUV ISO9001 and ISO13485[97]. - The company is enhancing its quality control products, which are essential for maintaining the accuracy of diagnostic tests[168]. - The company actively participates in the formulation of industry standards, having completed the assignment of values for 33 standard substances or national standards during the reporting period[99]. Supply Chain and Operational Efficiency - The company is enhancing its supply chain efficiency and investing in cold chain logistics to improve product delivery[39]. - The company has a strong emphasis on procurement, ensuring quality by purchasing raw materials in bulk for six months to a year[80]. - The company operates under a sales-driven production model, aligning production plans with customer orders and demand forecasts[82]. - The company is transitioning its sales model from a mix of direct and distributor sales to primarily distributor-based sales, especially in the domestic market[83]. Challenges and Risks - The company acknowledges the risk of raw material supply shortages due to reliance on imports and is working to increase self-sufficiency in raw material production[15]. - The company is adapting its operational strategies in response to new regulations in the medical device industry, which may impact its business operations[7]. - The company is closely monitoring changes in industry regulations and adjusting its business strategies accordingly to mitigate potential risks[10].

迈克生物股份有限公司 2021 年第三季度报告 1 证券代码：300463 证券简称：迈克生物 公告编号：2021-076 迈克生物股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|------------------------|--------------------------|-- ...

Group 1: Event Announcement - The company will participate in the "2021 Sichuan Listed Companies Investor Online Reception Day" on September 16, 2021, from 15:00 to 17:00 [1] - The event aims to address investor concerns regarding corporate governance, social responsibility/ESG, operational status, development strategy, risk management, market value management, and investor protection [1] Group 2: Participation Details - The event is organized by the Sichuan Listed Companies Association in collaboration with Shenzhen Panorama Network Co., Ltd. [1] - Key attendees include General Manager Mr. Wu Mingjian, Chief Financial Officer Mr. Liu Qilin, and Board Secretary Ms. Shi Wei [1] Group 3: Investor Engagement - Investors are encouraged to actively participate in the online discussion via the designated website: http://rs.p5w.net [1] - The company assures the accuracy and completeness of the announcement, emphasizing no false statements or significant omissions [1]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2021, representing a year-on-year increase of 20%[1] - The company's operating revenue for the first half of 2021 was ¥1,960,373,333.89, representing a 34.97% increase compared to ¥1,452,469,410.61 in the same period last year[37] - The net profit attributable to shareholders of the listed company was ¥531,681,926.41, a 71.36% increase from ¥310,277,168.88 in the previous year[37] - The net profit after deducting non-recurring gains and losses was ¥525,177,486.92, up 71.58% from ¥306,082,459.45 in the same period last year[37] - The net cash flow from operating activities reached ¥448,384,117.66, marking a significant increase of 173.86% compared to ¥163,727,700.01 in the previous year[37] - The basic earnings per share were ¥0.9563, reflecting a 71.20% increase from ¥0.5586 in the same period last year[37] - The company has outlined a revenue guidance of 1.2 billion RMB for the full year 2021, indicating a growth target of 15%[1] Market Expansion and Product Development - The company plans to launch three new products in Q3 2021, targeting a market expansion of 30% in the next fiscal year[1] - Market expansion efforts include entering two new provinces, aiming for a 10% market share in those regions by the end of 2022[1] - The company has established a full industry chain development layout, covering raw biological materials to specialized services[47] - The company launched 27 new products during the reporting period, including fully automated chemiluminescence analyzers and specific protein analyzers, enhancing its product portfolio and market share[64] - The company’s revenue model is based on providing comprehensive laboratory solutions, which has led to collaborative growth across various product lines[51] Research and Development - R&D investment increased by 25% to 50 million RMB, focusing on new diagnostic technologies[1] - The company continues to focus on the research and development of in vitro diagnostic products, with a comprehensive product range across various technology platforms[47] - The company has established a research and development platform that includes two major centers focusing on reagents and instruments, enhancing its innovation capabilities[51] - The company achieved a research and development investment of ¥111.15 million in the reporting period, representing a 21.81% increase from ¥91.25 million in the same period last year, with R&D investment accounting for 9.61% of self-produced product revenue[70] - The company has a workforce of 784 R&D personnel, accounting for 28.33% of total employees, with 378 focused on instrument development and 406 on reagents and raw materials[81] Competitive Landscape - The domestic IVD industry is characterized by low concentration and intense competition, with over 40 listed companies[58] - Currently, over 80% of the domestic IVD market is occupied by imported high-end products, indicating significant room for growth for domestic manufacturers[56] - The company aims to enhance its market competitiveness by promoting laboratory automation and intelligence, thereby increasing its domestic market share for self-developed products[51] - The company is facing intensified market competition, shifting from product sales to providing comprehensive solutions[114] Environmental and Compliance Efforts - The company has established a comprehensive quality management system to ensure product quality from raw materials to final products[114] - The company has implemented a waste classification initiative, investing a total of CNY 60,650, with 1,674 participants and 865 hours dedicated to the activities[150] - The company has established hazardous waste storage facilities, which are operating normally[149] - The company has completed internal approval for its environmental self-monitoring plan and is executing it in strict accordance with regulations[148] Shareholder and Stock Information - The company is not planning to distribute cash dividends or issue bonus shares for the half-year period[1] - A total of 5.372 million restricted stocks are planned to be granted to 98 employees under the 2018 stock incentive plan[1] - The company approved a share repurchase plan with a total fund of no less than RMB 150 million and no more than RMB 300 million, with a maximum repurchase price of RMB 60.00 per share[193] - As of June 30, 2021, the company repurchased a total of 3,844,966 shares, accounting for 0.69% of the total share capital, at an average price of RMB 44.26 per share, totaling RMB 170,181,678[193] Strategic Initiatives - The company is actively working on the layout of other product platforms and future competitive strategies[1] - The company is closely monitoring market changes and accelerating new product development in response to uncertainties in post-pandemic demand[116] - The company has established a wholly-owned subsidiary focused on the R&D and production of biochemical raw materials to mitigate supply risks[115]

COVID-19 Testing and Products - In 2020, the company achieved significant growth in demand for COVID-19 related testing products, leading to rapid development of related diagnostic products[19]. - The company received NMPA registration, CE certification, and FDA EUA for its COVID-19 testing kits, including the 2019-nCoV test kit (fluorescent PCR method) and antibody testing kits[19]. - The company’s COVID-19 testing products generated sales of 710 million yuan during the reporting period, contributing significantly to revenue growth[65]. - The company has successfully registered multiple COVID-19 testing products, including nucleic acid and antibody detection kits, enhancing its market position and competitive advantage[101]. - The registration of the new antibody testing kits for COVID-19 (IgG and IgM) demonstrates the company's responsiveness to market needs during the pandemic[143]. - The company is focusing on the development of rapid testing kits, which are crucial for timely diagnosis and treatment[168]. Financial Performance - The company reported a total revenue of 1.5 billion in 2020, representing a year-over-year growth of 20% compared to 1.25 billion in 2019[36]. - The company's operating revenue for 2020 was ¥3,703,877,006.69, representing a 14.92% increase compared to ¥3,222,956,019.79 in 2019[43]. - The net profit attributable to shareholders for 2020 was ¥793,917,986.86, a significant increase of 51.15% from ¥525,262,640.01 in 2019[43]. - The net cash flow from operating activities reached ¥1,094,048,810.10, marking a 138.09% increase compared to ¥459,516,311.64 in 2019[43]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[36]. - The company achieved a revenue of 3.704 billion yuan, representing a year-on-year growth of 14.92%[65]. - The net profit attributable to shareholders reached 794 million yuan, with a year-on-year increase of 51.15%[65]. Research and Development - The company is focused on enhancing its R&D capabilities and product structure to maintain competitiveness in the increasingly mature in vitro diagnostic industry[11]. - The company invested 200 million in R&D for new technologies, focusing on molecular diagnostics and rapid testing solutions[36]. - The company has established R&D centers focused on reagent and instrument development, fostering innovation through partnerships with medical institutions[61]. - The company invests 25% to 30% of its net profit annually into independent research and development, employing 767 R&D personnel, which accounts for 29.20% of the total workforce[88]. - The company has obtained 392 patents, including 148 invention patents, and has been recognized as a "National Enterprise Technology Center" by the National Development and Reform Commission[102]. - R&D investment reached CNY 235.01 million, a 24.10% increase from CNY 189.37 million in the previous year, accounting for 12.68% of self-produced product revenue[111]. Market Expansion and Strategy - The company plans to enter the European market in 2021, targeting a revenue contribution of 100 million within the first year[36]. - Market expansion efforts led to a 10% increase in market share in the Asia-Pacific region[36]. - The company has established partnerships with approximately 200 overseas distributors, covering 89 countries and regions, indicating significant market expansion potential[94]. - The company aims to enhance its market position through strategic partnerships and potential acquisitions in the healthcare sector[142]. - The company is actively pursuing market expansion strategies to increase its footprint in emerging markets[168]. - The company is focusing on self-declared registrations for its products in the EU and EEA markets, indicating a strategy to streamline market entry[156]. Product Development and Innovation - The company has developed a comprehensive product line in in vitro diagnostic products, covering biochemical, immunological, clinical, molecular diagnostics, rapid testing, pathology, and raw materials[57]. - The company launched 37 new products during the reporting period, including the fully automated chemiluminescence immunoassay analyzer i1000 and the fully automated blood cell analyzer F800[70]. - The company is committed to continuous innovation, as evidenced by the development of new assay kits for hormone measurement, such as the Anti-Müllerian Hormone Assay Kit[54]. - The company is enhancing its competitive position by diversifying its product range and targeting emerging markets for medical devices[156]. - The company is exploring strategic partnerships for market expansion and technology sharing to leverage synergies in product development[173]. - The company has introduced new technologies in its testing kits, improving accuracy and reliability in diagnostics[167]. Quality Management and Compliance - The company has a comprehensive quality management system certified by TUV ISO9001, ISO13485, and CQC ISO14001, achieving international advanced standards[94]. - The company emphasizes the importance of traceability in product quality, having established a traceability system recognized internationally[90]. - The company is focused on maintaining compliance with international regulatory standards to facilitate the approval and distribution of its products globally[156]. - The company has received emergency use authorization (EUA) for several COVID-19 testing kits, indicating a strong market presence in the diagnostics sector[168]. Operational Efficiency - The company has implemented an automated production line since 2018 to enhance quality control and minimize human error in production processes[10]. - The company operates on a sales-driven production model, aligning production with sales forecasts and customer orders[64]. - The company has established a unified procurement center responsible for sourcing raw materials, ensuring quality by purchasing six months to a year’s worth of supplies for reagent raw materials[64]. - The company has a production capacity of 7 million reagent boxes and 10,000 instruments annually, supported by a 2,000㎡ quality testing center[93].

Financial Performance - The company's revenue for Q1 2021 reached ¥1,069,535,881.25, representing a 106.14% increase compared to ¥518,832,353.21 in the same period last year[10] - Net profit attributable to shareholders was ¥313,335,250.80, a significant increase of 314.80% from ¥75,538,510.35 in the previous year[10] - The net profit after deducting non-recurring gains and losses was ¥310,711,565.81, up 298.37% from ¥77,995,048.19 year-on-year[10] - The basic earnings per share rose to ¥0.5643, reflecting a 313.10% increase compared to ¥0.1366 in the same quarter last year[10] - The company's operating revenue for Q1 2021 reached 1,069.54 million CNY, a year-on-year increase of 106.14%[25] - Net profit attributable to shareholders for Q1 2021 was 313.34 million CNY, up 314.80% compared to the same period last year[28] - The company reported a net profit of ¥2,090,483,609.45 for the period, up from ¥1,830,654,469.49, reflecting a growth of approximately 14.2%[90] - The total profit for the current period was ¥391,325,457.32, compared to ¥93,811,940.17 in the previous period, which is an increase of around 317.5%[98] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,630,517,914.16, an increase of 4.17% from ¥6,364,982,648.45 at the end of the previous year[10] - The total liabilities as of March 31, 2021, were CNY 3,188,859,307.22, compared to CNY 3,025,211,868.91 at the end of 2020, showing an increase of approximately 5.41%[74] - The total assets of the company as of March 31, 2021, amounted to ¥5,511,475,460.13, compared to ¥5,154,352,698.31 at the end of December 2020, indicating an increase of about 6.9%[90] - The total liabilities increased to ¥2,096,168,655.03 from ¥1,942,167,193.04, reflecting a rise of approximately 7.9%[90] - The company reported a short-term loan of CNY 973,832,110.05, which increased from CNY 921,547,655.36, reflecting a rise of about 5.67%[76] Cash Flow - The net cash flow from operating activities was ¥86,679,373.91, which is a 21.00% increase from ¥71,637,790.83 in the same period last year[10] - Cash inflow from operating activities totaled CNY 1,015,206,612.88, up from CNY 687,761,691.21 year-over-year[110] - Cash outflow for purchasing goods and services was CNY 569,055,767.80, an increase from CNY 406,506,851.18[114] - Cash inflow from financing activities was CNY 379,059,665.73, compared to CNY 326,993,526.16 in the previous period[116] - The company reported a net increase in cash and cash equivalents of CNY -48,433,450.16, compared to CNY 242,221.32 in the previous period[116] Research and Development - The company's R&D investment in Q1 2021 was 50.96 million CNY, a year-on-year increase of 26.89%[30] - The company is actively engaging in research and development of new products and technologies, focusing on the development of chemiluminescence immunoassay instruments and related products[69] - Research and development expenses increased to ¥39,826,443.24 from ¥25,311,159.91, marking a rise of about 57.5%[1] Shareholder and Investment Activities - The company plans to raise funds through a private placement of shares, which has been approved by the China Securities Regulatory Commission[36] - The company has committed to invest RMB 50 million in the Chengdu Biocity Puhua Maike Industrial Investment Fund, representing 5% of the fund's total size of RMB 1.5 billion[42] - The company has approved a share repurchase plan with a total amount not less than RMB 150 million and not exceeding RMB 300 million, with a maximum repurchase price of RMB 60.00 per share[46] - The company is focused on strategic investments and partnerships to drive growth and market expansion in the biotechnology sector[42] Market and Sales Performance - The sales revenue from self-developed products reached 682.12 million CNY, a year-on-year increase of 278.14%[28] - The company experienced a slight overachievement in sales revenue from COVID-19 testing products due to increased demand around the Spring Festival[34] - Sales of the company's self-developed routine products have shown a recovery growth, supported by ongoing market promotion and brand influence[32] Compliance and Governance - The company has made commitments to compensate investors for any losses caused by false statements or omissions in the prospectus during the IPO[56] - The company has adhered to the share lock-up commitment for 12 months from the date of the IPO for its directors and senior management[59] - The company is actively managing its share repurchase strategy in accordance with market conditions and regulatory requirements[48]

Financial Performance - Operating revenue for the quarter was ¥1,077,075,543.66, representing a year-on-year growth of 29.68%[10] - Net profit attributable to shareholders was ¥255,795,010.13, a significant increase of 76.73% compared to the same period last year[10] - Basic earnings per share for the quarter were ¥0.4598, up 75.50% from the previous year[10] - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q3 2020[48] - The company's total revenue for the current period reached ¥558,289,365.14, a significant increase from ¥279,015,048.99 in the previous period, representing a growth of approximately 100.5%[91] - Net profit for the current period was ¥267,911,935.74, up from ¥114,015,736.77 in the previous period, reflecting a growth of approximately 134.1%[96] - The total operating profit for the current period was ¥651,617,274.84, up 65.7% from ¥392,898,021.77[109] Cash Flow and Assets - The net cash flow from operating activities was ¥200,705,886.05, showing a remarkable increase of 288.07% year-on-year[10] - Cash flow from operating activities amounted to ¥364,433,586.06, significantly up from ¥85,881,503.63 in the prior year[115] - Cash and cash equivalents at the end of the period increased to 288,132,329.40 from 122,932,432.90 in the previous period[125] - The company's cash and cash equivalents amounted to CNY 500,219,085.24, up from CNY 443,905,616.02 in December 2019, indicating an increase of about 12.5%[62] - Total assets at the end of the reporting period reached ¥6,205,875,250.68, an increase of 12.90% compared to the previous year[10] - The total assets of the company stood at 5,496,843,872.67, remaining stable compared to the previous period[129] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,362[14] - The largest shareholder, Tang Yong, holds 12.21% of the shares, amounting to 68,062,301 shares[14] - The company plans to repurchase and cancel a total of 368,045 restricted shares due to non-compliance with performance targets by certain incentive recipients[31] - The management team has successfully completed their share lock-up commitments, ensuring shareholder confidence[49] Government Support and Subsidies - The company received government subsidies amounting to ¥22,536,424.81, which increased due to revenue-related support[10] - Other income increased by 245.04% year-on-year, mainly due to increased government subsidies related to income[26] Research and Development - Development expenditures increased by 43.93% compared to the beginning of the year, reflecting the company's commitment to R&D investment[25] - Research and development expenses for the current period were ¥36,556,336.46, compared to ¥30,519,714.97 in the previous period, showing an increase of approximately 19.8%[83] - Research and development expenses rose to ¥66,130,053.20, compared to ¥50,164,606.56 in the previous period, marking a 31.9% increase[109] Inventory and Receivables - Accounts receivable increased by 2.69% compared to the beginning of the year, due to enhanced collection efforts[25] - Inventory increased by 34.44% compared to the beginning of the year, driven by increased raw material reserves to meet market demand and mitigate supply chain risks from the pandemic[25] Future Outlook - The company expects to maintain a growth rate of 20% for the next quarter, driven by new product launches and market expansion[50] - Future outlook includes continued recovery from the impacts of COVID-19 and plans for market expansion and potential mergers and acquisitions[57] Financial Stability and Governance - There were no violations regarding external guarantees during the reporting period, ensuring financial stability[52] - There were no non-operational fund occupations by controlling shareholders during the reporting period, reflecting good governance practices[53]